Clinical Trial Update: Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma

View source ↗

Summary

The IND expanded access program for Janssen's CAR-T therapy for multiple myeloma is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carvykti (ciltacabtagene autoleucel)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Status: NO_LONGER_AVAILABLE